Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock

Halozyme Therapeutics Inc.’s only clinical drug candidate PEGPH20 will exit the stage – along with the company’s oncology operations – now that the drug has failed to show an improvement in overall survival versus the standard of care in pancreas cancer in the Phase III HALO-301 clinical trial. The spotlight now will focus entirely on the Enhanze drug delivery platform as Halozyme restructures to support its existing partners, including two with product approvals anticipated next year.

The San Diego-based company announced on 4 November that while first-line treatment with PEGPH20 in combination with Celgene Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

20 May 2025

• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

19 May 2025

• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

19 May 2025

• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.